CAPTRUST Financial Advisors
NBIX icon

CAPTRUST Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.64M Buy
45,360
+7,776
+21% +$1.15M 0.01% 654
2026
Q1 		$4.95M Buy
37,584
+6,656
+22% +$883K 0.01% 772
2025
Q4 		$4.39M Buy
30,928
+2,877
+10% +$417K 0.01% 713
2025
Q3 		$3.94M Buy
28,051
+15,875
+130% +$2.15M 0.01% 728
2025
Q2 		$1.53M Buy
12,176
+4,866
+67% +$558K ﹤0.01% 1107
2025
Q1 		$808K Sell
7,310
-4,334
-37% -$549K ﹤0.01% 1387
2024
Q4 		$1.59M Buy
11,644
+1,836
+19% +$227K ﹤0.01% 984
2024
Q3 		$1.13M Buy
9,808
+52
+0.5% +$7.13K ﹤0.01% 1122
2024
Q2 		$1.34M Buy
9,756
+1,598
+20% +$219K ﹤0.01% 987
2024
Q1 		$1.13M Sell
8,158
-3,673
-31% -$502K ﹤0.01% 1065
2023
Q4 		$1.56M Buy
11,831
+8,355
+240% +$962K 0.01% 1027
2023
Q3 		$391K Buy
3,476
+493
+17% +$51.9K ﹤0.01% 1813
2023
Q2 		$281K Buy
2,983
+100
+3% +$9.77K ﹤0.01% 2024
2023
Q1 		$292K Sell
2,883
-63
-2% -$6.56K ﹤0.01% 1765
2022
Q4 		$352K Buy
2,946
+1,017
+53% +$119K ﹤0.01% 1542
2022
Q3 		$205K Buy
1,929
+265
+16% +$26.9K ﹤0.01% 1810
2022
Q2 		$162K Buy
1,664
+270
+19% +$24.9K ﹤0.01% 1848
2022
Q1 		$131K Sell
1,394
-105
-7% -$8.9K ﹤0.01% 2064
2021
Q4 		$128K Buy
1,499
+232
+18% +$21.3K ﹤0.01% 1961
2021
Q3 		$122K Buy
1,267
+31
+3% +$2.93K ﹤0.01% 1915
2021
Q2 		$120K Buy
1,236
+205
+20% +$19.6K ﹤0.01% 1880
2021
Q1 		$100K Buy
+1,031
New +$108K ﹤0.01% 1952
2019
Q4 		– Sell
-107
Closed -$10K – 1502
2019
Q3 		$10K Hold
107
– – ﹤0.01% 1502
2019
Q2 		$9K Hold
107
– – ﹤0.01% 1531
2019
Q1 		$9K Buy
+107
New +$8.94K ﹤0.01% 1415
2018
Q4 		– Sell
-154
Closed -$19K – 1639
2018
Q3 		$19K Buy
+154
New +$17.5K ﹤0.01% 1026

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CAPTRUST Financial Advisors's NBIX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Neurocrine Biosciences (NBIX) stake by 21% in Q2 2026, buying an estimated $1.15M and bringing the position to 45,360 shares worth $7.64M. The position accounts for 0.01% of the portfolio, ranked #654.

CAPTRUST Financial Advisors first reported a position in NBIX in Q3 2018 and has held it in 26 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • CAPTRUST Financial Advisors held 45,360 shares of Neurocrine Biosciences worth $7.64M as of Q2 2026.
  • CAPTRUST Financial Advisors bought 7,776 Neurocrine Biosciences shares in Q2 2026, an estimated $1.15M.
  • Neurocrine Biosciences made up 0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #654 holding.
  • CAPTRUST Financial Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 26 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.